Histone deacetylases are key enzymes of epigenetic regulation and are therefore involved
in crucial cellular events like transcription, differentiation, apoptosis and cell division. The …

В руководстве с современных позиций освещены вопросы этиологии, патогенеза,
классификации, диагностики и лечения множественной миеломы. В основу работы …

Encouraging progress has been made in the treatment of patients with relapsed/refractory
multiple myeloma (MM). The rapidly evolving understanding of key pathways responsible for …

The most common subtypes of primary cutaneous T-cell lymphoma (CTCL) are mycosis
fungoides and Sézary syndrome. Clinical manifestations and prognosis in CTCL are highly …

Advancement in the understanding of cancer development in recent years has identified
epigenetic abnormalities as a common factor in both tumorigenesis and refractory disease …

Romidepsin (Istodax®, depsipeptide, FR901228, FK228, NSC 630176) is a cyclic peptide,
broad-spectrum, potent histone deacetylase inhibitor, with activity mainly against class I …

Использование новых подходов в лечении рецидивов и рефрактерных форм
множественной миеломы (ММ) привело к существенному улучшению показателей …

HDAC, by modifiing relations between DNA and histones, are major proteins of the
epigenetic regulation. They play part in the signal transduction and in many cellular …

Peripheral T-cell lymphoma (PTCL) is comprised of a rare heterogeneous group of diseases
with diverse clinical presentations; however outcomes associated with conventional …

Romidepsin is a histone deacetylase inhibitor recently approved by the FDA for the
treatment of cutaneous T-cell lymphoma. It has led to protracted responses in a significant …